Antibiotic Use and Prescribing Patterns for Respiratory Tract Infections (ICD-10: J00-J99) in Indonesia During the COVID-19 Pandemic
Article Sidebar
Main Article Content
Page: 837-846
Abstract
Introduction: Respiratory tract infections (RTIs) contribute substantially to global antibiotic consumption, raising concerns about antimicrobial resistance (AMR). This study aimed to analyze antibiotic prescribing patterns for respiratory disorders in an Indonesian teaching hospital during the COVID-19 pandemic. Methods: This retrospective, cross-sectional study examined systemic antibiotic prescriptions based on the Anatomical Therapeutic Classification (ATC: J01) for respiratory diseases (ICD-10: J00-J99) at Cilacap Government Teaching Hospital between January and December 2021. Data were extracted from electronic medical records (e-MR), including patient demographics (i.e. age and sex), ICD codes and name of antibiotics. We analyzed WHO AWaRe classifications, administration routes, and seasonal patterns based on patient’s entry and antibiotic use. Results: The study included 2,395 patients with antibiotic prescriptions for respiratory disorders. The Watch group antibiotics accounted for 85.6% of prescriptions, with the highest use among adults (86.2%). Parenteral administration (71.5%) was more common than oral administration (28.5%). Pneumonia (38.2%) and chronic obstructive pulmonary disease (27%) were the most common indications. Antibiotic use peaked in December (n=529) and was lowest in July (n=84). Ceftriaxone (n=838), azithromycin (n=270), cefixime (n=262), levofloxacin (n=216), and meropenem (n=56) were among the top prescribed antibiotics. Conclusion: The study highlights the predominant use of broad-spectrum and parenteral antibiotics for respiratory disorders, raising concerns about AMR. Factors such as seasonality, disease patterns, and diagnostic challenges may have influenced prescribing practices. Implementing antimicrobial stewardship programs, promoting evidence-based guidelines, and addressing modifiable risk factors are crucial to combat AMR and optimize patient outcomes during and beyond the COVID-19 pandemic.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Lalmohamed A, Venekamp RP, Bolhuis A, Souverein PC, van de Wijgert JH, Gulliford MC, et al. Within-episode repeat antibiotic prescriptions in patients with respiratory tract infections: a population-based cohort study. Journal of Infection. 2024;88(4):106135. DOI: https://doi.org/10.1016/j.jinf.2024.106135
WHO G. Antimicrobial Resistance [Internet]. 2022 [cited 2024 May 10]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
Childs A, Zullo AR, Joyce NR, McConeghy KW, van Aalst R, Moyo P, et al. The burden of respiratory infections among older adults in long-term care: a systematic review. BMC geriatrics. 2019;19:1–10. DOI: https://doi.org/10.1186/s12877-019-1236-6
CDC. Antibiotic use in the United States, 2021 update: progress and opportunities [Internet]. 2021 [cited 2024 Oct 5]. Available from: https://www.cdc.gov/antibiotic-use/pdfs/stewardship-report-2021-H.pdf
Otia M, Dubey A. Antibiotics over usage: a vital contributor of antibiotic resistance. International journal of therapeutic innovation. 2024;2:0130–7. DOI: https://doi.org/10.55522/ijti.V2I2.0030
CDC. Core elements of antibiotic stewardship for nursing homes [Internet]. 2021 [cited 2024 Oct 5]. Available from: https://www.cdc.gov/antibiotic-use/core-elements/nursing-homes.html
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372. DOI: https://doi.org/10.1136/bmj.n71
Wong VWY, Huang Y, Wei WI, Wong SYS, Kwok KO. Approaches to multidrug-resistant organism prevention and control in long-term care facilities for older people: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control. 2022;11(1):7. DOI: https://doi.org/10.1186/s13756-021-01044-0
Ramdhani D, Azizah SN, Kusuma SAF, Sediana D. Antibiotic resistance: Evaluation of levofloxacin treatment in acute respiratory tract infections cases at the Tasikmalaya City Health Center, Indonesia. Journal of Advanced Pharmaceutical Technology & Research. 2020;11(3):113–6. DOI: https://doi.org/10.4103/japtr.JAPTR_17_20
Kurniawati F, Munif Yasin N, Azizah SN, Purbaningtyas SA. The impact of suitability of empirical antibiotics use on therapeutic outcome of respiratory tract infection patients at inpatient wards of Universitas Gadjah Mada Academic Hospital. Journal of Basic and Clinical Physiology and Pharmacology. 2021;32(4):767–71. DOI: https://doi.org/10.1515/jbcpp-2020-0452
Wardani RL, Suharjono, Kuntaman, Widjaja A. Antibiotic use on acute respiratory tract infection nonpneumonia and nonspecific diarrhea in Primary Health Care Centre in Banjarbaru City, South Kalimantan, Indonesia. Journal of Basic and Clinical Physiology and Pharmacology. 2021;32(4):729–35. DOI: https://doi.org/10.1515/jbcpp-2020-0417
WHO. WHO Access, Watch, Reserve (AWaRe) Classification of Antibiotics for Evaluation and Monitoring of Use; [Internet]. 2023 [cited 2024 May 8]. Available from: https://www.who.int/publications/i/item/2021-aware-classification
Bulfone TC, Malekinejad M, Rutherford GW, Razani N. Outdoor transmission of SARS-CoV-2 and other respiratory viruses: a systematic review. The Journal of infectious diseases. 2021;223(4):550–61. DOI: https://doi.org/10.1093/infdis/jiaa742
Morici G, Cibella F, Cogo A, Palange P, Bonsignore MR. Respiratory effects of exposure to traffic-related air pollutants during exercise. Frontiers in Public Health. 2020;8:575137. DOI: https://doi.org/10.3389/fpubh.2020.575137
Allinson JP, Chaturvedi N, Wong A, Shah I, Donaldson GC, Wedzicha JA, et al. Early childhood lower respiratory tract infection and premature adult death from respiratory disease in Great Britain: a national birth cohort study. The Lancet. 2023;401(10383):1183–93. DOI: https://doi.org/10.1016/S0140-6736(23)00131-9
Cohen S. Psychosocial vulnerabilities to upper respiratory infectious illness: implications for susceptibility to coronavirus disease 2019 (COVID-19). Perspectives on Psychological Science. 2021;16(1):161–74. DOI: https://doi.org/10.1177/1745691620942516
Kemenkes RI. Polusi Udara Sebabkan Angka Penyakit Respirasi Tinggi [Internet]. Kementerian Kesehatan Republik Indonesia. 2023 [cited 2025 May 11]. Available from: https://kemkes.go.id/id/polusi-udara-sebabkan-angka-penyakit-respirasi-tinggi
Jang W, Kim B. The effect of a parenteral-to-oral conversion program for high-bioavailability antibiotics use. Antimicrobial Stewardship & Healthcare Epidemiology. 2022;2(S1):s3–4. DOI: https://doi.org/10.1017/ash.2022.60
Hoque MN, Akter S, Mishu ID, Islam MR, Rahman MS, Akhter M, et al. Microbial co-infections in COVID-19: Associated microbiota and underlying mechanisms of pathogenesis. Microbial Pathogenesis. 2021;156:104941. DOI: https://doi.org/10.1016/j.micpath.2021.104941
Lazar M, Sandulescu M, Barbu EC, Chitu-Tisu CE, Andreescu DI, Anton AN, et al. The role of cytokines and Molecular pathways in Lung Fibrosis following SARS-CoV-2 infection: a physiopathologic (re) view. Biomedicines. 2024;12(3):639. DOI: https://doi.org/10.3390/biomedicines12030639
Li X, Wu Z, Xue M, Du W. Smoking status affects clinical characteristics and disease course of acute exacerbation of chronic obstructive pulmonary disease: a prospectively observational study. Chronic Respiratory Disease. 2020;17:1479973120916184. DOI: https://doi.org/10.1177/1479973120916184
Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. European journal of clinical microbiology & infectious diseases. 2021;40(5):905–19. DOI: https://doi.org/10.1007/s10096-020-04138-6
Ito S, Muraki Y, Inose R, Mizuno K, Goto R, Kiyosuke M, et al. Characteristics of pediatric patients claimed with acute upper respiratory infection during otorhinolaryngology consultations: A descriptive study of a large Japanese medical claims database. Journal of Infection and Chemotherapy. 2024; DOI: https://doi.org/10.1016/j.jiac.2024.01.015
Qudah T, Alameri MA, Alqudah A, Al Meslamani A, Iqbal S. Knowledge, Attitudes, and Practices (KAP) of community pharmacists regarding antibiotic use and resistance: a cross-sectional study from the United Arab Emirates. International Journal of Environmental Health Research. 2024;1–13. DOI: https://doi.org/10.1080/09603123.2024.2339534
Yang X, Li X, Qiu S, Liu C, Chen S, Xia H, et al. Global antimicrobial resistance and antibiotic use in COVID-19 patients within health facilities: a systematic review and meta-analysis of aggregated participant data. Journal of Infection. 2024;106183. DOI: https://doi.org/10.1016/j.jinf.2024.106183
Tang K, Zhao H. Quinolone antibiotics: Resistance and therapy. Infection and Drug Resistance. 2023;811–20. DOI: https://doi.org/10.2147/IDR.S401663
Joel JJ, Bhat VS, ER AR, others. Study on drug utilization pattern of antibiotics in respiratory tract infections. Research Journal of Pharmacy and Technology. 2019;12(3):1189–92. DOI: https://doi.org/10.5958/0974-360X.2019.00197.5
Buonavoglia A, Leone P, Solimando AG, Fasano R, Malerba E, Prete M, et al. Antibiotics or no antibiotics, that is the question: an update on efficient and effective use of antibiotics in dental practice. Antibiotics. 2021;10(5):550. DOI: https://doi.org/10.3390/antibiotics10050550
Parra-Lara LG, Martínez-Arboleda JJ, Rosso F. Azithromycin and SARS-CoV-2 infection: where we are now and where we are going. Journal of global antimicrobial resistance. 2020;22:680. DOI: https://doi.org/10.1016/j.jgar.2020.06.016
Pani A, Lauriola M, Romandini A, Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. International journal of antimicrobial agents. 2020;56(2):106053. DOI: https://doi.org/10.1016/j.ijantimicag.2020.106053
WHO. Clinical management of COVID-19 - Living guideline [Internet]. 2023 [cited 2024 May 29]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.2
Timsit JF, Depuydt P, Kanj SS. When should I start broad-spectrum antibiotics? Intensive Care Medicine. 2024 Nov 1;50(11):1908–11. DOI: https://doi.org/10.1007/s00134-024-07654-7